For the quarter ending 2025-09-30, CYCN made $875,000 in revenue. -$976,000 in net income. Net profit margin of -111.54%.
| Income Statement | 2025-09-30 | 2025-03-31 | 2024-12-31 | |
|---|---|---|---|---|
| Total revenues | 875,000 | 81,000 | 602,000 | |
| Research and development | 348,000 | 36,000 | 68,333.333 | |
| General and administrative | 1,533,000 | 1,502,000 | 1,367,000 | |
| Impairment loss | - | - | 0 | |
| Total cost and expenses | 1,881,000 | 1,538,000 | 1,435,333.333 | |
| Loss from operations | -1,006,000 | -1,457,000 | -833,333.333 | |
| Interest income | 30,000 | - | 55,333.333 | |
| Gain from settlement of account payable | 0 | - | 0 | |
| Gain from insurance recovery | 0 | - | - | |
| Total other income, net | 30,000 | - | 55,333.333 | |
| Net loss from continuing operations | - | - | -778,000 | |
| Gain from discontinued operations | - | - | 0 | |
| Net loss | -976,000 | - | -778,000 | |
| Foreign currency translation adjustment loss | 0 | - | - | |
| Comprehensive loss | -976,000 | - | - | |
| Earnings per share, diluted | -0.3 | -0.56 | -0.307 | |
| Net loss per share - basic | -0.3 | -0.56 | -0.307 | |
| Weighted average shares used in calculating net loss per share - basic | 3,225,000 | 2,556,000 | -2,666.667 | |
| Weighted average shares used in calculating net loss per share - diluted | 3,225,000 | 2,556,000 | -2,666.667 | |
Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)